Response to ‘Osteodystrophy and dialysis survival’  by Kalantar-Zadeh, K. et al.
declared that, ‘The evidence is here,’ in reference to a Wyeth
product. These bands convey the impression of a connection
between scientific evidence for the products, the pharma-
ceutical company, and the independent academic journal.
The November editions of the Journal of the American
Society of Nephrology, American Journal of Kidney Diseases,
and Kidney International contained 30, 19, and 13 advertise-
ments, respectively. Of these three journals, the November
issue of Kidney International actually had the lowest number
of large page advertisements. However, unlike these other
journals, advertisements in Kidney International were not
limited to the pages preceding and following the contents of
the journal but were interspersed. These observations raise
the question of whether journals face a trade-off between
running a larger number of appropriate advertisements or a
lesser number of (presumably more lucrative) inappropriate
advertisements in order to cover costs.
To avoid risking the loss of respect of its readers, we urge
Kidney International to eliminate practices that blur the
boundary between academic pursuits and advertising. If we
are incapable of self-regulation, it will only be a matter of
time before the government steps in to control advertising
practices in medical journals.
1. The New York Times Company Journalism Ethics Policy
http://www.nytco.com/company-journalism-ethics.html.
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To the Editor: In the article by Kalantar-Zadeh 1 we noticed
with interest that the survival benefit granted by paricalcitol
paradoxically decreased with higher doses. Since the latter
doses are more likely to be hyperphosphatemic and
hypercalcemic, this suggests that these deleterious side effects
counterbalance the beneficial effects of paricalcitol related to
partial correction of the usual vitamin D depletion of the
American Dialysis population. Indeed vitamin D deficiency
has been epidemiologically related to a higher risk of diabetes
and cardiovascular risk by activation of inflammation and
this can simply be suppressed by plain vitamin D adminis-
tration.2 This simple measure can furthermore quite
efficiently suppresses parathyroid hormone (PTH) and allow
to limit the dose of the more potent (inappropriately called
‘active’) vitamin D derivatives, while decreasing the risk of
calcification. This is strongly suggested by the comparison of
2 cohorts of young adults with childhood onset of end-stage
renal disease (ESRD):3,4 the Berlin cohort 4 had received
cholecalciferol and a 35-fold lower cumulative dose of ‘active’
vitamin D than that of Heidelberg and its coronary
calcification prevalence was 10% instead of 92%, while their
PTH suppression and demographic characteristics (with the
exception of 2 years less on dialysis and 2 years more on
transplantation) were comparable.
These observations should lead to systematic correction of
vitamin D deficiency, even in dialysis patients, even though
NKF-K/DOQI does recommend it only in chronic kidney
disease (CKD) patients stage 3–4, but paradoxically not in
ESRD patients in whom vitamin D deficiency is more severe.
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We appreciate the comments by Bonne et al.1 The apparent
mitigation of the survival advantage of higher doses of
vitamin D was only observed with paricalcitol doses above
15 mcg/week.2 Patients in the latter group had an average
serum intact PTH concentration of 555 pg/ml, compared
with 268 pg/ml in all other patients.2 Hence, the weaker
survival advantage in the high-dose paricalcitol group is
not unlikely due to a high baseline PTH at the start of the
cohort. Both we2 and others3 have shown that severe
hyperparathyroidism is associated with increased death
risk. Such excessive serum PTH concentrations usually
lead to secondary administration of higher doses of
vitamin D by nephrologists. The resultant ‘selection bias
by indication’ may appear in the form of a spurious
association between vitamin D dose and outcome. Never-
theless, it should be emphasized that in our study even
patients who had received the highest paricalcitol dose
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(415 mg/week) exhibited significantly improved survival
compared with those who did not receive paricalcitol
during any calendar quarter.2 Indeed, additional subgroup
analyses have shown that the survival advantage of any
dose of paricalcitol is robust and observed in all categories
of maintenance dialysis patients irrespective of the serum
concentration of calcium, phosphorus or PTH.4 The latter
data are consistent with subgroup analyses by Teng et al.,5
who also showed survival advantages of every dose of
vitamin D analog across diverse subgroups.
We agree with Bonne et al. that vitamin D deficiency
may be an underappreciated problem in patients with
chronic kidney disease and it is currently highly prevalent
in dialysis patients.6 However, regardless of the degree
of vitamin D deficiency, therapy with paricalcitol
was associated with better survival. Vitamin D deficiency
may be associated with both inflammation and athero-
sclerosis.7 Hence, administration of a 1-hydroxylated form
of vitamin D appears advantageous both biologically and
epidemiologically.
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